Cambridge Pancreatic Cancer Symposium 2019
The next symposium will be held on 9th – 10th May at the Cancer Research UK Cambridge Institute, University of Cambridge. The programme for the symposium can be found here.
Registration has now closed. Please contact Aarthi.Gopinathan@cruk.cam.ac.uk if you have any questions.
- Due to the current cashless system at the Cambridge Institute, symposium attendees will be unable to use the cafeteria on-site to purchase refreshments. We apologise for any inconvenience this may cause.
- There is no assigned visitor parking for the institute. Symposium attendees will have to park at one of the on-site public car parks. Please see the site map for details.
Lynn M. Matrisian, PhD, MBALynn is Chief Science Officer at the Pancreatic Cancer Action Network, based in Manhattan Beach, CA and Washington DC, USA. She focuses on understanding and impacting the scientific and medical activities within the pancreatic cancer field to advance the organizations goal to double survival from pancreatic cancer by the year 2020.
Pr L. ZitvogelPr L. Zitvogel, clinical oncologist and research director, has been actively contributing to the field of cancer immunology and immunotherapy since 1992. She brought together basic and translational research, including the design of cancer therapies through combined animal studies and Phase I patient trials.
Dr. Cristian TomasettiCristian is an Associate Professor at Johns Hopkins University with appointments in the Division of Biostatistics and Bioinformatics, Department of Oncology (Sidney Kimmel Comprehensive Cancer Center) and the Department of Biostatistics (Bloomberg School of Public Health).
Christine Iacobuzio-Donahue MD PhDChristine is a board certified Anatomic Pathologist with specialty training in gastrointestinal pathology and cancer genetics. She currently serves as an Attending Physician in Pathology, Director of the David M. Rubenstein Center for Pancreatic Cancer Research, and Director of the Medical Donation (Rapid Autopsy) Program at Memorial Sloan Kettering Cancer Center in New York City, NY.
Ken OliveKen began his doctoral studies in 1998 in the laboratory of Tyler Jacks at the MIT Center for Cancer Research, investigating the neomorphic effects of mutant p53 in a mouse model of Li-Fraumeni Syndrome. While at MIT, he also helped develop a conditional mutant model of advanced lung adenocarcinoma.
Stephan HerzigStephan is Director of the Institute for Diabetes and Cancer (IDC) at Helmholtz Center Munich (HMGU), full professor for molecular metabolic control at the medical faculty of the Technical University Munich and honorary professor at the University of Heidelberg.
Dr John MaherDr John Maher leads the "CAR Mechanics" group within King's College London, which is focused on the development of adoptive immunotherapy using CAR and gamma delta T-cells. He played a key role in the early development of second generation CAR technology and is chief investigator of a Phase 1 CAR T-cell clinical trial in head and neck cancer.
Dr. Christian FrezzaDr. Christian Frezza is Programme leader at the MRC Cancer Unit, Cambridge Cancer Center, at the University of Cambridge, UK. He studied Medicinal Chemistry at the University of Padova, Italy, and gained his MSc in 2002, after a period of research on mitochondrial toxicity induced by photoactivable anticancer drugs.
Stephen PereiraDr. Christian Stephen Pereira, Professor of Hepatology & Gastroenterology at UCL and Honorary Consultant Gastroenterologist in PancreaticoBiliary Medicine at University College Hospital and The Royal Free Hospital. The research interests of the Centre for HPB Cancer within the UCL Division of Medicine concentrate on the pathogenesis, diagnosis and treatment of biliary tract and pancreatic cancer, as well as the benign conditions primary sclerosing cholangitis and autoimmune pancreatitis
The Cambridge Pancreatic Cancer Centre gratefully acknowledges support from the following organisations for providing funding for the symposium: